Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)- Insider Own39.59% Shs Outstand92.70M Perf Week0.26%
Market Cap742.91M Forward P/E- EPS next Y-4.20 Insider Trans-0.03% Shs Float58.74M Perf Month15.58%
Income- PEG- EPS next Q-0.99 Inst Own71.21% Short Float10.97% Perf Quarter-13.08%
Sales- P/S- EPS this Y66.16% Inst Trans- Short Ratio5.34 Perf Half Y-71.71%
Book/sh7.53 P/B1.01 EPS next Y41.09% ROA- Short Interest6.45M Perf Year-
Cash/sh8.11 P/C0.94 EPS next 5Y- ROE- 52W Range5.70 - 29.88 Perf YTD2.41%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-74.43% Beta-
Dividend TTM- Quick Ratio11.88 Sales past 5Y0.00% Gross Margin- 52W Low34.04% ATR (14)0.56
Dividend Ex-Date- Current Ratio11.88 EPS Y/Y TTM- Oper. Margin- RSI (14)50.33 Volatility9.23% 6.65%
Employees51 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.86 Target Price23.67
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-452.98% Payout- Rel Volume0.51 Prev Close7.64
Sales Surprise- EPS Surprise-86.70% Sales Q/Q- EarningsNov 07 AMC Avg Volume1.21M Price7.64
SMA20-0.51% SMA504.07% SMA200-48.03% Trades Volume620,650 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-13-23Initiated Wells Fargo Equal Weight $11
Dec-08-23Initiated Citigroup Neutral $8
Sep-13-23Downgrade Morgan Stanley Overweight → Equal-Weight $19
Sep-05-23Initiated H.C. Wainwright Buy $44
May-30-23Initiated TD Cowen Outperform
May-30-23Initiated Piper Sandler Overweight $68
May-30-23Initiated Morgan Stanley Overweight
May-30-23Initiated Jefferies Buy $31
Feb-15-24 04:05PM
Jan-10-24 11:30AM
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
04:30PM Loading…
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
Dec-12-23 09:25PM
Dec-11-23 09:35AM
Dec-04-23 03:00PM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
07:24AM Loading…
Nov-27-23 09:09PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
Nov-07-23 05:11PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
07:22PM Loading…
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lin Shao-LeeChief Executive OfficerJan 02Sale7.4110,69179,1881,603,036Jan 04 06:09 PM
Westlake BioPartners Fund II, 10% OwnerMay 09Buy18.001,250,00022,500,0009,790,729May 11 09:16 PM
SEIDENBERG BETH CDirectorMay 09Buy18.001,250,00022,500,0009,790,729May 11 09:13 PM
SEIDENBERG BETH CDirectorMay 09Buy18.0060,0001,080,00060,000May 11 09:13 PM
Gosebruch Henry ODirectorMay 09Buy18.0050,000900,00050,000May 11 09:06 PM
Svoronos DawnDirectorMay 09Buy18.0015,000270,00015,000May 11 09:11 PM
Peloso PaulChief Medical OfficerMay 09Buy18.006,000108,0006,000May 11 08:54 PM
Dier MardiCFO and CBOMay 09Buy18.005,556100,0085,556May 11 08:51 PM
Kim MinaChief Legal & Admin. OfficerMay 09Buy18.005,00090,0005,000May 11 08:58 PM
Becker Daniel J.DirectorMay 09Buy18.003,00054,0003,000May 11 09:02 PM
Dier MardiCFO and CBOMay 09Buy18.001,75031,500875May 11 08:51 PM
Oyston RonaldChief People OfficerMay 09Buy18.001,00018,0001,000May 11 09:00 PM
Oyston RonaldChief People OfficerMay 09Buy18.002646826May 11 09:00 PM